Shanghai Generon Initiates a Phase II Trial for Breast Cancer in the US

Published: May 09, 2012

2012-5-9--Shanghai Generon announced that it will initiate a randomized, multi-center Phase 2 clinical trial in the US in breast cancer patients receiving myelotoxic chemotherapy. The company believes F-627 is one of the first innovative biologic drug candidates developed by a Chinese biotech company to enter global clinical development. More details…

Back to news